Knockdown of AT-rich interaction domain (ARID) 5B gene expression induced AMPKα2 activation in cardiac myocytes

Lisa Hirose-Yotsuya1,*, Fumio Okamoto1,2, Takahiro Yamakawa1, Robert H. Whitson1, Yoko Fujita-Yamaguchi1,3, Keiichi Itakura1

1 Department of Molecular & Cellular Biology, Beckman Research Institute of City of Hope, Duarte, California, USA; 2 Emergency Medicine and Cardiology of Takatsuki Red Cross Hospital, Osaka, Japan; 3 Department of Diabetes Complications & Metabolism, Beckman Research Institute of City of Hope, Duarte, California, USA.

Summary This study demonstrated that ARID5B mRNA is present in mouse cardiomyocyte HL-1 cells, and that ARID5B siRNA constantly knocked down ARID5B gene expression to the 40% level of control. AMPKα2 protein was elevated in such ARID5B knockdown HL-1 cells, and this was accompanied by an increase in the level of phosphorylated AMPKα. Since AMPKα2 mRNA levels did not change in ARID5B knockdown cells, the stability of AMPKα2 protein was investigated using inhibitors for protein synthesis and proteasomal degradation. Treatment of HL-1 cells with either cycloheximide or MG132 caused an appreciable increase in the amount of AMPKα2 protein in ARID5B knockdown cells, which suggests that knockdown of ARID5B mRNA extends the half-life of AMPKα2 protein in HL-1 cells via yet unidentified mechanisms. As for the expected downstream consequences of AMPKα2 activation, we found thus far that glucose uptake, fatty acid uptake, or fatty acid oxidation remained unchanged in HL-1 cells after knockdown of ARID5B. Further studies are required to understand the mechanisms for ARID5B knockdown and resulting AMPKα2 activation, and also to identify which metabolic pathways are affected by AMPKα2 activation in these cells. In summary, this study provided the foundation for an in vitro cell culture system to study possible roles of ARID5B in cardiomyocytes.

Keywords: Mrf-2, ARID5B, downregulation by siRNA, AMPKα2 activation, cardiac myocytes, HL-1 cells

1. Introduction

ARID5B (AT-rich interaction domain-containing protein 5B) was previously known as Mrf-2 (modulator recognition factor 2). It was identified in our laboratory in 1996 as a novel nuclear protein that binds to sequences upstream of the human cytomegalovirus major immediate-early enhancer/promoter and exerts repressor activity in undifferentiated human Tera-2 cells (1). Subsequent studies revealed the three-dimensional structure of the novel DNA-binding motif (ARID) of Mrf-2 and mechanisms of DNA recognition (2-4). The ARID family of DNA-binding proteins has grown since then to include fifteen proteins found in humans and most other vertebrate species, and six proteins found in Drosophila as well as proteins found in worms, fungi, plants and yeast (5-8). The ARID family is divided into six sub-families. In addition to a variety of roles as transcription factors in cell growth, differentiation, and development (6), a number of studies have suggested that proteins in most of the ARID sub-families are involved in cancer as tumor suppressors or promoters (8). A notable exception is the ARID5 sub-family which consists of two members, Mrf-1/ARID5A and Mrf-2/ARID5B (7,8). Mrf-2/ARID5B is expressed in various tissues including mouse cardiac and vascular tissues, where it seems to regulate smooth muscle cell differentiation and proliferation (9), lung, kidney, and brain as well as less abundantly in adrenal gland, spleen and thymus (10). Important roles of ARID5B in growth, immune, and sexual development have been
suggested (10). While the role of ARID5B in cancer
is still elusive, previous studies suggested that genetic
variations in the ARID5B gene are associated with
susceptibility to coronary atherosclerosis or type 2
diabetes in Japanese populations (11,12).

Targeted disruption of the ARID5B gene resulted in
slower neonatal weight gains, high rates of mortality in
neonates, and significant reductions in adult weight and
adiposity (13). This suggested that ARID5B is essential
for embryonic development and accumulation of lipids in
postnatal life. Studies using mouse embryonic fibroblasts
(MEFs) derived from $ARID5B^{-/-}$ embryos and $ARID5B^{+/+}$
littermate controls demonstrated that adipogenesis in
$ARID5B^{-/-}$ MEFs was significantly lower than that in
$ARID5B^{+/+}$ MEFs, but was restored when ARID5B
was expressed in $ARID5B^{-/-}$ MEFs (14). Similarly, the
expression of multiple adiogenic genes was inhibited
following transient transfection of siRNA targeting
ARID5B in 3T3-L1 cells (14). Since a role of ARID5B
in the regulation of metabolism has been suggested
(11-13), we investigated the potential involvement of
ARID5B and AMP-activated protein kinase (AMPK) in
the metabolism of cardiac myocytes.

AMPK has been known as a sensor and regulator
of energy balance at the cellular level as well as at
the whole body level by responding to hormonal and
nutrient signals (15-17). Multiple AMPK subunit
isoforms encoded by distinct genes were identified
with two α subunits (α1 and α2), two β subunits
(β1 and β2), and three γ subunits (γ1, γ2, and γ3)
(15,16). The α subunit is a kinase which is activated
by phosphorylation in response to an increase in the
AMP:ATP ratio. Binding of AMP to the γ subunit of the
AMPK $αβγ$ complex induces conformational changes
in the α subunit kinase leading to the critical Thr172
phosphorylation by its upstream kinases. Although the
mechanisms of these signaling pathways are not fully
understood, it has been well-documented that activation
of AMPK in skeletal and cardiac muscles is induced by
metabolic stress and whole-body energy status as well
as the AMPK mimic AICAR and diabetic drugs such as
metformin (15,18,19).

Previous studies showed that AICAR increased
glucose uptake in heart muscle, indicating that AMPK
may be involved in GLUT4 translocation (20), and that
AMPK and PI-3K/Akt had an additive effect on
oxidative stress-mediated GLUT4 translocation in
cardiac myocytes (21). Furthermore, mice lacking
AMPKa2 or expressing dominant negative AMPKa2
inhibited the ischemia-induced stimulation of glucose
uptake in cardiac myocytes (22-24). These studies
strongly suggested that AMPKa2 plays an important
role in regulating cardiac glucose metabolism and
protecting the heart from metabolic stresses.

The current study tested the hypothesis that ARID5B
plays a role in glucose metabolism via the AMPK
signaling pathway in cardiac myocytes. We found that
when siRNA was introduced to HL-1 cardiomyocytes,
ARID5B mRNA was significantly reduced, and that
the levels of both total and phosphorylated AMPKa2
subunit were significantly increased. The mechanism
and functional consequences of the AMPKa2 activation
induced by ARID5B knockdown in HL-1 cells were
also investigated. Although not conclusive, this study
provided a good model system for further studying the
role of ARID5B knockdown in AMPKa2 signaling
pathways.

2. Materials and Methods

2.1. Materials

Mouse HL-1 cardiomyocytes were provided by Dr. W.
Claycomb (Louisiana State University Health Science
Center, New Orleans, LA) (25,26). Claycomb medium,
fetal bovine serum (FBS), penicillin-streptomycin,
norepinephrine, L-glutamine, trypsin-EDTA, trypsin
inhibitor, fibronectin, cytochalasin B, cycloheximide,
and MG132 were purchased from Sigma-Aldrich.
L-Ascorbic acid sodium salt was from Mallinckrodt.

Opti-MEM and Lipofectamine® RNAiMAX
Transfection Reagent were from Life technologies.

Bacto gelatin, ON-TARGETplus Mouse ARID5B
siRNA-SMART pool (siRNA), ON-TARGETplus Non-
targeting Pool (control scramble RNA), Tris-HEPES
gels, and 20× Tris-HEPES buffer for sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) were obtained from Thermo Fisher Scientific.
Polyvinylidene difluoride (PVDF) membrane was from
GE Healthcare Life Sciences. 10× TBS was from Bio-
Rad. Non-fat milk was from Labscientific, Inc. HyGLO
Chemiluminescent HRP Antibody Detection Reagent
was from Denville Scientific Inc. 2-Deoxy-D-[3H]
glucose and [3H]palmitic acid were from American
Radiolabel Chemicals.

2.2. Cell culture

HL-1 cells were grown as monolayer cultures in flasks,
dishes, and plates precoated with 2 μg/cm² fibronectin
dissolved in 0.02% gelatin. HL-1 cells were maintained
in Claycomb medium supplemented with 10% FBS, 2
mM L-glutamine, 0.1 mM norepinephrine (prepared
freshly from 10 mM stock solution in 30 mM L-ascorbic
acid), and 100 μg/mL penicillin-streptomycin. Cells
were grown at 37°C in an atmosphere of 5% CO2.
The medium was changed every other day.

2.3. siRNA transfection

The transfection procedure is summarized in Figure
1. We used a commercially-available mixture of four
double-stranded siRNAs with the following sequences
on the sense strand; 5’-acaauaauugacgguaa-3’,

www.biosciencetrends.com
5'-guguagagucgccacaa-3', 5'-cggagaaguccguggau-3', and 5'-ggucuaeuuaaaggacua-3'. These siRNA's target exons 5, 4-plus-5, 10, and 4, respectively of ARID5B. Cells were seeded in 24-well plates, 12-well plates, or 35 mm dishes (2.5 × 10⁴ cells/cm²), and transfected 24 h after seeding. At that time (40-50% confluence), the cells were incubated for 2-3 h in Claycomb medium without penicillin and streptomycin, then transfected with 50 nM siRNA or control scramble RNA using Lipofectamine® RNAiMAX Transfection Reagent. After 24 h, the medium was replaced by Claycomb medium without penicillin and streptomycin. Cells were used for molecular and cellular experiments at 48 h post-transfection. To confirm the effect of siRNA, cells were lysed with 700 μL of Qiazol (Qiagen), and RNA was isolated with Qiagen RNeasy®. ARID5B mRNA level was determined by quantitative real-time PCR as described in section 2.4.

2.4. Quantitative real-time PCR

Total RNA samples (1 μg) were reverse-transcribed with High-Capacity cDNA Reverse Transcription Kit (Life technologies), and the resulting cDNA samples were amplified with the specific primer pairs for mouse ARID5B and Rpl19 as a control housekeeping gene using qSYBR Green Super Mix (Bio-Rad). The sequences of specific primer pairs used were as follows. ARID5B forward, 5'-agaaaaaacgccatcgagc-3'; reverse, 5'-ctccctagattaccacctae-3' and Rpl19 forward, 5'-ctcccaggattaccacctaac-3' and reverse, 5'-gagaaaaacgccatcgagc-3'. The reaction was performed using the following temperature cycles, initial denaturation at 95°C for 10 min followed by 40 cycles of amplification at 95°C for 10 sec and 56°C for 30 sec (ARID5B), or 40 cycles of amplification at 95°C for 10 sec and 61°C for 30 sec (Rpl19). The mRNA expression level was determined using the CFX96 real-time detection system (Bio-Rad). Relative gene expression was calculated using the ΔΔCT method.

2.5. Western blotting analysis

At 48 h post-transfection, cells were washed twice with ice-cold PBS and lysed using ice-cold cell lysis buffer (50 mM HEPES, pH 7.4, containing 2 mM Na₂VO₄, 10 mM Na₃P₂O₇, 10 mM NaF, 2 mM EDTA 2Na, 2 mM EGTA, and 0.2 mM PMSF). After incubation on a shaker for 15 min at 4°C, cell lysates were centrifuged at 14,000 rpm at 4°C for 15 min. Protein concentrations in the cleared lysates were measured by BCA assay (Thermo Fisher Scientific). Samples of 10-20 μg were subjected to SDS-PAGE using Tris-HEPES gels and then transferred to PVDF membranes. The membranes were blocked with 5% non-fat milk in TBST buffer (TBS containing 0.1% Tween 20) for 1 h at room temperature. After blocking, membranes were incubated at 4°C overnight with the following primary antibodies; anti-phospho-AMPKα (1:1000, #2535) and anti-AMPKα (1:1000, #2603) from Cell Signaling Technology, anti-AMPKα2 (1:1000, ab97275) from Abcam, anti-EFTUD2 (1:2000, 10208-1-AP) from Proteintech, and anti-GAPDH (1:10000, AM4300) from Ambion. Subsequently, the membranes were washed 3 times with TBST for 5 min and incubated with HRP-conjugated anti-rabbit IgG (#170-6515, Bio-Rad) or HRP-conjugated anti-mouse IgG (sc-2005, Santa Cruz) for 1 h at room temperature. Then, the membranes were washed 4 times with TBS containing 0.1% Tween 20 and 0.1% Triton X-100 for 5 min at room temperature, then incubated with HyGLO Chemiluminescent HRP Antibody Detection Reagent. The membranes were exposed to X-ray film, and the protein bands on the films were quantified using Image J software.

2.6. Analysis of AMPKα2 protein stability

HL-1 cells in 35 mm dishes were transfected with siRNA as described in section 2.3, and at 48 h post-transfection, the growth medium was changed to medium containing 5 μg/mL cycloheximide (CHX) or 10 μM MG132, a proteasomal degradation inhibitor. Cells were harvested at different time points after CHX or MG132 treatment, and AMPKα2 and GAPDH protein levels were determined by Western blotting.

2.7. Glucose and fatty acid uptake assays in HL-1 cells

Cells were grown in 24-well plates and transfected with siRNA as described in section 2.3. Cells were washed with KRPH buffer (130 mM NaCl, 4.7 mM KCl, 1.24 mM MgSO₄, 2.5 mM CaCl₂, 1 mM HEPES, 2.5 mM NaH₂PO₄) once at 48 h post-transfection. Then cells were incubated in 250 μL of fresh KRPH buffer for 15 min at 37°C. For the glucose uptake assay, HL-1 cells were incubated with [3H]2-deoxy-D-glucose (10 μM; 137.5 μCi/well) for 10 min at 37°C. The incubation medium was aspirated, then the cells were washed four times with ice-cold PBS and solubilized by adding 100 μL of 0.5 M NaOH to each well. Aliquots of the cell extracts were transferred to vials for scintillation counting. In order to determine the level of non-specific background, cells in replicate wells were pretreated with 20 μM cytochalasin B for 15 min at 37°C, incubated with [3H]2-deoxy-D-glucose, and processed in the same way. Aliquots of the same cell extracts were used for determining protein concentrations by BCA assay. Results were calculated as pmol of glucose uptake per min per mg of protein.

For fatty acid uptake assays, cells were incubated for 15 min at 37°C in KRPH buffer, and [3H] palmitic acid (40 μM; 10.5 μCi/well) was added to each well. After a 20 min-incubation at 37°C, the medium was removed, the cells were washed 4 times with ice-cold
PBS, and solubilized with 100 μL of 0.5 M NaOH per well. The radioactivity in both the incubation medium and the cell lysate from each well were measured by scintillation counting. The percentage of fatty acid uptake was calculated by dividing $^3$H in the cell lysate by total $^3$H from both the cell lysate and incubation medium.

2.8. Positron Emission Tomography (PET) for glucose uptake in the heart of ARID5B knockout mice

Animal studies were approved by the City of Hope Animal Care and IACUC. Generation of the total body ARID5B knockout mice has been previously described (13). Mice were housed in a temperature-controlled environment with a 12 h light: 12 h dark cycle and allowed ad libitum access to standard chow and water.

Thirty two week-old male mice were used for these experiments. The $^{18}$F-flurodeoxyglucose ($^{18}$F-FDG) radio-tracer was obtained from the City of Hope radiopharmacy. The mice were imaged at the City of Hope Small Animal Imaging Core on two days: On the first day, two ARID5B$^{-/-}$ males and one ARID5B$^{+/+}$ male littermate control were imaged; on the second day, one ARID5B$^{-/-}$ male and two ARID5B$^{+/+}$ male littermate controls were imaged. The average weight for the ARID5B$^{-/-}$ males was 25.7 ± 4.0 grams; the average weight for the ARID5B$^{+/+}$ males was 41.3 ± 4.1 grams ($p < 0.05$). Prior to imaging, the mice were placed in individual cages with Sani-chip bedding, and fasted overnight (from 5:30 PM to 9:00 AM). The mice were placed in a cage with a warming light for 15 min prior to injection via the tail vein with 121-177 μCi of $^{18}$F-FDG, and then moved to cages without warming lights for uptake periods of 58-60 min. Following the uptake period, tail regions of the mice were imaged for 2 min to insure that there was no extravasation of the tracer from the injection site. The mice were imaged for 10 min while under isoflurane anesthesia. Following the imaging scans, the mice were euthanized under isoflurane, and various organs and tissues were harvested. The tissue samples were weighed, and the $^{18}$F in each sample was measured using a gamma counter. The CPM values were corrected for the radioactive decay that occurred in the interval following the injection. Imaging data were analyzed using the ASI-Pro software package. Specific uptake values in the heart were estimated as follows. The PET images were rotated so that a series of transverse optical sections of the heart could be analyzed. In each optical section both the heart plus the enclosed blood space and the blood space alone were analyzed by defining the appropriate regions of interest. The volume of heart tissue was calculated as the volume of heart-plus-blood minus the volume of blood alone. Similarly, the total DPM of $^{18}$F per cc in the heart was as calculated by subtracting the blood space values from the heart-plus-blood space values. Specific uptake values are expressed as (DPM/cc tissue)/(injected dose in μCi/ml blood). The blood volume was calculated as 5.85% of total body weight.

2.9. Statistics

Data are expressed as mean ± SEM. Differences were evaluated by two-tailed Student $t$ test. Statistical significance was set at $p < 0.05$.

3. Results

3.1. ARID5B gene expression was reduced in HL-1 cardiomyocytes by siRNA

The siRNA transfection protocol as schematically illustrated in Figure 1 was used throughout this study.

Figure 1. Schematic diagram of the siRNA transfection protocol used in this study. HL-1 cardiomyocytes were seeded in 24-well plates, 12-well plates, or 35 mm dishes with a density of 2.5 × 10$^4$ cells/cm$^2$. Cells were cultured for 24 h to reach 40-50% confluence (inset, left panel) before transfection of siRNA or control scramble RNA as described in Methods. At 24 h post-transfection (inset, right panel), the medium was replaced with fresh medium to allow HL-1 cells to recover. At 48 h post-transfection, cells were subjected to various analyses.
HL-1 cardiomyocytes were cultured for 24 h to allow them to attach to the plates (Figure 1 insets, left panel) before being treated with siRNA or scramble RNA for 24 h. The transfection medium was replaced with fresh culture medium and the resulting HL-1 cardiomyocytes were subjected to cellular and molecular analyses at 48 h post-transfection (Figure 1 insets, right panel).

In each experiment, the level of ARID5B expression in HL-1 cells was determined by quantitative real-time PCR. The results of nine independent experiments showed that the mRNA level in cells treated with ARID5B siRNA was always ~38% of the value for cells treated with control scramble RNA (Mean ± SE: 37.7 ± 2.1 %, n = 9, p < 0.001). Results of representative experiments are shown in Figures 2A, 3A, 4A, and 5A. This indicates not only that ARID5B mRNA is present in HL-1 cells, but also that siRNA efficiently knocked down gene expression.

3.2. Both AMPKα2 protein and AMPKα phosphorylation levels were elevated by knockdown of ARID5B mRNA

After confirming siRNA downregulated ARID5B mRNA (Figure 2A), we determined AMPKα protein levels by Western blotting. As seen in Figure 2B, Western blotting analysis of cell lysates with anti-AMPKα1 or anti-AMPKα2 antibody clearly showed that the AMPKα2 protein level was significantly increased in cells transfected with ARID5B siRNA, but that no change was observed in the AMPKα1 protein level (Figure 2B). Quantitation of immunostained bands from four experiments revealed an average increase of 1.4-fold (1.4 ± 0.15, n = 4, p < 0.05) in AMPKα2 protein level (Figure 2C, right panel) but no change in the AMPKα1 protein level (Figure 2C, left panel).

The phosphorylation status of T172 of AMPKα was also determined by Western blotting using anti-phospho AMPKα. This monoclonal antibody was produced by immunizing animals with a synthetic phospho-peptide corresponding to amino acid residues surrounding Thr172 of human AMPKα protein. Because this amino acid sequence is conserved between mouse and humans and between AMPKα1 and AMPKα2 in both species, the antibody recognizes phospho-Thr172 in both AMPKα1 and AMPKα2. Thus, in order to assess AMPKα phosphorylation, the levels of total AMPKα protein (AMPKα1 plus α2) and AMPKα phosphorylation were determined by Western blotting using anti-phospho-AMPKα antibody.

3.3. Both AMPKα1 and AMPKα2 protein levels were similar after knockdown of ARID5B mRNA

Since we showed that ARID5B knockdown in HL-1 cells significantly increased AMPKα2 expression, we next determined AMPKα1 and AMPKα2 protein levels by Western blotting. The results showed that knockdown of ARID5B mRNA did not change AMPKα1 protein expression but did increase AMPKα2 protein levels (Mean ± SE: 1.4 ± 0.15, n = 4, p < 0.05). The phosphorylation status of AMPKα1 was also increased by knockdown of ARID5B mRNA (Figure 3A), whereas AMPKα2 phosphorylation was not affected by ARID5B knockdown (Figure 3B). These results indicate that ARID5B knockdown is sufficient to increase AMPKα2 expression and AMPKα1 phosphorylation.

Figure 2. AMPK protein expression levels in control and ARID5B knockdown HL-1 cells. A: HL-1 cells were seeded in 12-well plates. siRNA efficiency was confirmed by qPCR at 48 h post-transfection. B: The levels of AMPK α1 and α2 proteins were examined by Western blotting with subunit-specific antibodies. Cell lysates (10-20 μg of protein per lane) were subjected to SDS-PAGE and immunoblotted as described in Methods. EFTUD2 was used as a loading control. A representative Western blotting result of four independent experiments is shown. C: Quantitation of AMPKα1 or α2 bands (n = 4; *p < 0.05). D: Total AMPKα protein and total AMPKα phospho-protein levels were examined by Western blotting. Cell lysates (10 μg protein per lane) were subjected to SDS-PAGE and blotted with primary antibodies as described in Methods. EFTUD2 was used as a loading control. A representative result of four independent experiments is shown. E: Quantification of AMPKα or phospho-AMPKα bands as shown in D (n = 4; *p < 0.05). In A, C, and E, shown are results from control (■) and ARID5B siRNA experiments (□).
and the combined levels of phosphorylated AMPKα1 plus α2 were measured by Western blotting. Figure 2D clearly shows an increase in the amount of total AMPKα protein. Since the experiments shown in Figures 2B and 2C indicate that AMPKα2 increases while AMPKα1 does not, it is clear that the increase in total AMPKα protein is due solely to the increase in AMPKα2. Figure 2E (right panel) revealed the increase in total AMPKα (1.4 ± 0.13 -fold, \( n = 4, p < 0.05 \)), which is consistent with the increase in AMPKα2 shown in Figure 2C (right panel). Figure 2D and E clearly show that the increase in total phospho-AMPKα (1.8 ± 0.28 -fold, \( n = 4, p < 0.05 \)) is also significant and even greater than the increase in total AMPKα. Although other possibilities must be considered, these results, taken together, strongly suggest that ARID5B knockdown resulted in the increase in AMPKα2 protein and in phospho-AMPKα2, which is indicative of AMPKα2 activation.

3.3. Knockdown of ARID5B mRNA extended the half-life of AMPKα2 protein

In order to understand the mechanisms by which ARID5B knockdown increases AMPKα2 levels, we first compared AMPKα2 mRNA levels in cells transfected with siRNA or control scramble RNA. The results showed no difference (data not shown), which suggested that ARID5B is not involved in transcriptional regulation of AMPKα2. Next, we investigated the stability of AMPKα2 protein. Cells transfected with siRNA or control scramble RNA (Figure 3A) were subjected to treatment with cycloheximide (CHX) or MG132, and their effects on inhibition of AMPKα2 protein synthesis or proteasomal degradation were measured. A representative result from two CHX experiments is shown in Figures 3B and 3C. In the absence of CHX, the level of AMPKα2 protein was elevated by ARID5B knockdown HL-1 cells by more than 2-fold (compare Figure 3B lanes 1 and 5). In the presence of CHX the level of AMPKα2 protein declined rapidly at 30 min, then recovered slowly over the next 2 h in the control cells (Figure 3B lanes 1-4). In contrast, the levels of AMPKα2 protein remained elevated in ARID5B knockdown cells for 1 h, even when compared to the levels of AMPKα2 protein in control cells in the absence of CHX (compare Figure 3B lanes 1 to lanes 6 and 7). These results suggest that AMPKα2 protein appears more stable when ARID5B mRNA level is reduced.

When cells were treated with 10 μM MG132, a slight increase in AMPKα2 protein was seen in the control cells after 4 and 8 h-incubation (Figures 3D and 3E). This indicated that AMPKα2 protein is being accumulated in HL-1 cells due to the inhibition of proteasome-mediated protein degradation as expected. In siRNA-transfected cells, a significant elevation of AMPKα2 protein (an average of 4-fold at 0 h) was observed, again confirming the results described in section 3.2. The effect of MG132 was also seen in an accumulation of AMPKα2 protein after 4 or 8 h-incubation but to a lesser extent (Figures 3D and 3E), which may indicate that the AMPKα2 protein expression had already saturated at 0 h of MG132 treatment in cells when ARID5B mRNA was knocked down.

The results shown in Figure 3 thus suggested that knockdown of ARID5B mRNA most likely extended the half-life of AMPKα2 protein. It remains to be answered how ARID5B controls the stability of AMPKα2 protein.
In order to investigate whether a decrease in the correlation of glucose uptake and AMPK activation could be attributed to a decrease in HL-1 cells.

These effects, though small, positively demonstrated the increase in the phosphorylation of AMPKα2. Thus, in knockdown HL-1 cells, and this was accompanied by an increase in AMPKα2 protein levels were elevated in ARID5B knockdown. No difference in fatty acid uptake was, however, observed between control and ARID5B knockdown.

Next, we investigated possible physiological consequences of high levels of activated AMPKa2 protein which is considered to be a sensor and regulator of energy balance at the cellular level. Since AMPKa2 activation clearly occurs in the ARID5B knockdown cells, glucose uptake, one of possible physiological consequences of high levels as described in Methods, was measured in cells transfected with siRNA and control scramble RNA. The results, which are summarized in Figures 4A and 4B, did not show any significant differences in glucose uptake in those cells, however. Glucose uptake in HL-1 cardiomyocytes did respond to the AMPK mimetic AICAR which we used for control experiments. When added at 0.5 mM to the media 1 h prior to glucose uptake experiments, AICAR stimulated glucose uptake in non-treated and scramble RNA-treated cells increased 1.2 ± 0.13 (n = 3, p > 0.05) and 1.3 ± 0.03 (n = 3, p < 0.01)-fold, respectively. These effects, though small, positively demonstrated the correlation of glucose uptake and AMPK activation in HL-1 cells.

In order to investigate whether a decrease in

Generally speaking, the adult heart utilizes fatty acids as its main energy source (27). Thus, it can be speculated that fatty acid utilization may be affected by ARID5B knockdown. No difference in fatty acid uptake was, however, observed between control and ARID5B knockdown HL-1 cells (Figure 5).

3.4. Glucose uptake in ARID5B knockdown HL-1 cells and hearts of ARID5B knockout mice

3.5. Fatty acid uptake in ARID5B knockdown HL-1 cells

We demonstrated that siRNA efficiently knocked down ARID5B gene expression (to an average of 38% of control levels) in mouse cardiomyocyte HL-1 cells. AMPKα2 protein levels were elevated in ARID5B knockdown HL-1 cells, and this was accompanied by an increase in the phosphorylation of AMPKα2. Thus, in short, this study provided the foundation for an in vitro cell culture system to study possible roles of ARID5B in cardiomyocytes. This experimental in vitro cell culture may be useful in studying cardiac metabolism in pathophysiological conditions such as diabetic cardiomyopathy (28).

It has been well documented that activation of AMPK increases glucose uptake. Specifically, activation of AMPK via AICAR increased glucose uptake in

ARID5B expression affects glucose uptake in live animals, positron emission tomography (PET) for glucose uptake in the hearts of wild-type and ARID5B knockout mice (n = 3) was performed. Although some tendency of a slight increase was observed in glucose uptake in the hearts of ARID5B knockout mice as compared to that in the hearts of wild type mice, the difference was not statically significant (Figure 4C).
heart muscle (20) and in cardiac myocytes (21). Mice lacking AMPKα2 or expressing dominant negative AMPKα2 showed an inhibition of ischemia-induced stimulation of glucose uptake in cardiac muscle (22-24). In HL-1 cells it has been shown that insulin or the AMPK activator oligomycin stimulated glucose uptake by inducing translocation of GLUT4 (30). Adiponectin treatment also enhanced glucose and fatty acid uptake in HL-1 cells, and these effects were accompanied by increased AMPK phosphorylation (31). Based on previous reports, AMPKα2 activation in ARID5B knockdown HL-1 cells would be expected to result in increase in glucose and/or fatty acid uptake. When the functional consequences of the AMPKα2 activation induced by ARID5B knockdown in HL-1 cells were evaluated, however, under the culture conditions used in this study, we did not observe changes in glucose uptake (Figure 4), glycolysis (data not shown), fatty acid uptake (Figure 5), and fatty acid oxidation (data not shown). Further studies are obviously required to identify which metabolic pathways are affected by AMPKα2 activation in HL-1 cells.

Since AMPKα2 mRNA levels were not affected by ARID5B knockdown in HL-1 cells, the stability of AMPKα2 protein was investigated using an inhibitor of protein synthesis (CHX) and an inhibitor of the proteasome degradation pathway (MG132). AMPKα2 protein levels remained significantly elevated for an hour following CHX treatment in ARID5B knockdown HL-1 cells, while AMPKα2 protein levels fell dramatically in control cells. These results indicated that ARID5B knockdown extends the half-life of AMPKα2 protein in HL-1 cells. On the other hand, MG132 increased AMPKα2 protein levels three-fold in control cells, but had no effect in ARID5B knockdown HL-1 cells. It should be noted that the level of AMPKα2 protein in MG132-treated control cells was only half that of untreated ARID5B knockdown cells, even after eight hours of treatment. Wang et al. showed that calorie restriction (CR) increased the protein level of AMPKα2 and phosphorylation of AMPKα2 in skeletal muscle of wild-type mice, and that these changes in skeletal muscle contributed to an increase in whole body insulin sensitivity (32). CR did not increase insulin sensitivity in AMPKα2−/− mice. They also demonstrated that CR serum increased the stability of AMPKα2 protein in C2C12 myoblasts by inhibiting ubiquitination of AMPKα2 (32). Another study showed that life-long CR elicits a myocardial phenotype that is profoundly protected against ischemia/reperfusion injury, and that AMPK activation may play an important role in this process (33). It has been suggested that ubiquitination of AMPK in the heart may play a significant role in the etiology of cardiac diseases, and that this process presents an attractive target for developing novel therapies (34). In this regard, our finding that ARID5B may de-stabilize AMPKα2 protein in cardiomyocytes is intriguing. Whether or not the regulation of AMPK by ubiquitination is involved in this phenomenon requires further investigation.

In summary, this study provided the foundation for an in vitro cell culture system to study possible roles of ARID5B in cardiomyocytes. Further studies are required to understand the link between ARID5B knockdown and resulting AMPKα2 activation and the possible involvement of the ubiquitin proteasome system in AMPKα2 activation.

Acknowledgements

We thank Drs. W. Claycomb and M. Lam of LSU Health Science Center for providing us with HL-1 cells and very helpful instructions on culture conditions. The author (L. H.-Y.) also thanks members of Dr. Itakura’s laboratory for their continuous support and encouragement, and for Drs. M. Matsumoto and M. Kasuga at Research Institute National Center for Global Health and Medicine for their support.

References


(Received November 20, 2015; Revised December 20, 2015; Accepted December 20, 2015)